Madhukar Misra, MD
Nephrology · Columbia, MONPI 1851342158
Payments from drug & device makers
Across 53 payments — averaging $47.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$2K
- Travere Therapeutics, Inc.$167
- Otsuka America Pharmaceutical, Inc.$114
- Novartis$113
- Calliditas Therapeutics US Inc.$92
- Vantive US Healthcare LLC$80
- plus $461 from 13 others
What the payments were for
- Speaking & faculty fees$1,35053%
- Travel & lodging$201%
- Food & beverage$1,16746%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 2 | $1,511 |
| Travere Therapeutics, Inc. | 13 | $167 |
| Otsuka America Pharmaceutical, Inc. | 6 | $114 |
| Novartis | 4 | $113 |
| Calliditas Therapeutics US Inc. | 3 | $92 |
| Vantive US Healthcare LLC | 2 | $80 |
| Baxter Healthcare | 2 | $67 |
| Vifor Pharma, Inc. | 3 | $55 |
| Mallinckrodt Hospital Products Inc. | 3 | $50 |
| Akebia Therapeutics Inc | 3 | $46 |
| Sanofi | 2 | $45 |
| Amgen(2 entities) | 2 | $38 |
| Rockwell Medical, Inc. | 2 | $32 |
| Chiesi USA, Inc. | 1 | $31 |
| Mozarc Medical US LLC | 1 | $23 |
| Bayer | 1 | $21 |
| GSK | 1 | $21 |
| Ardelyx, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $13 |
How this compares
$2,537 in reported general payments places this provider in the 65th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 50 | $9,437 |
| Nifedipine ErNifedipine | 48 | $1,251 |
| Calcium Acetate | 19 | $1,081 |
| Metoprolol Succinate | 13 | $379 |
| Hydralazine Hcl | 12 | $249 |
| Metolazone | 12 | $231 |
| Amlodipine Besylate | 27 | $185 |
| Losartan Potassium | 30 | $152 |
| Gabapentin | 11 | $118 |
| Lisinopril | 15 | $108 |
| Spironolactone | 14 | $67 |
| Carvedilol | 16 | $29 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Columbia
- Adam Whaley-ConnellColumbia$193K
- Kunal ChaudharyColumbia$185K
- Preethi YerramColumbia$126K
- Zbylut TwardowskiColumbia$43K
- John VanstoneColumbia$28K
- Ramesh KhannaColumbia$14K
- Ahmed AwadKansas City$12.4M
- Benjamin HumphreysSaint Louis$1.2M
- Donovan PolackFlorissant$782K
- Derek LarsonCreve Coeur$605K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.